Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.

Ruiz AJ, Hadac EM, Nace RA, Russell SJ.

J Virol. 2016 Mar 28;90(8):4078-4092. doi: 10.1128/JVI.02810-15. Print 2016 Apr.

2.

PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ.

J Virol. 2013 Apr;87(7):3752-9. doi: 10.1128/JVI.02832-12. Epub 2013 Jan 16. Erratum in: J Virol. 2015 Feb;89(4):2453.

3.

Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions.

Hadac EM, Federspiel MJ, Chernyy E, Tuzikov A, Korchagina E, Bovin NV, Russell S, Henry SM.

J Virol Methods. 2011 Sep;176(1-2):78-84. doi: 10.1016/j.jviromet.2011.06.005. Epub 2011 Jun 14.

PMID:
21703308
4.

Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.

Hadac EM, Kelly EJ, Russell SJ.

Mol Ther. 2011 Jun;19(6):1041-7. doi: 10.1038/mt.2011.68. Epub 2011 Apr 19.

5.

MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference.

Kelly EJ, Hadac EM, Cullen BR, Russell SJ.

PLoS Pathog. 2010 Mar 19;6(3):e1000820. doi: 10.1371/journal.ppat.1000820.

6.

Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.

Carlson SK, Classic KL, Hadac EM, Dingli D, Bender CE, Kemp BJ, Russell SJ.

AJR Am J Roentgenol. 2009 Jan;192(1):279-87. doi: 10.2214/AJR.08.1205.

7.

Engineering microRNA responsiveness to decrease virus pathogenicity.

Kelly EJ, Hadac EM, Greiner S, Russell SJ.

Nat Med. 2008 Nov;14(11):1278-83. doi: 10.1038/nm.1776. Epub 2008 Oct 26.

PMID:
18953352
8.

In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography.

Carlson SK, Classic KL, Hadac EM, Bender CE, Kemp BJ, Lowe VJ, Hoskin TL, Russell SJ.

Mol Imaging Biol. 2006 Nov-Dec;8(6):324-32.

PMID:
17053863
9.

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.

Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM, Soeffker D, Federspiel MJ, Russell SJ.

Cancer Gene Ther. 2006 Aug;13(8):732-8. Epub 2006 Mar 10.

PMID:
16543921
10.
11.

Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.

Dong M, Hadac EM, Pinon DI, Miller LJ.

Mol Pharmacol. 2005 Jun;67(6):1892-900. Epub 2005 Mar 17.

PMID:
15774770
12.

Reengineering paramyxovirus tropism.

Hadac EM, Peng KW, Nakamura T, Russell SJ.

Virology. 2004 Nov 24;329(2):217-25.

14.

Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor.

Zang M, Dong M, Pinon DI, Ding XQ, Hadac EM, Li Z, Lybrand TP, Miller LJ.

Mol Pharmacol. 2003 May;63(5):993-1001. Erratum in: Mol Pharmacol. 2003 Ju;;64(1):193.

PMID:
12695527
15.

Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling.

Coulie B, Matsuura B, Dong M, Hadac EM, Pinon DI, Feighner SD, Howard AD, Miller LJ.

J Biol Chem. 2001 Sep 21;276(38):35518-22. Epub 2001 Jul 18.

16.

Molecular characterization and organ distribution of type A and B cholecystokinin receptors in cynomolgus monkey.

Holicky EL, Hadac EM, Ding XQ, Miller LJ.

Am J Physiol Gastrointest Liver Physiol. 2001 Aug;281(2):G507-14.

17.

Upregulation of secretin receptors on cholangiocytes after bile duct ligation.

Tietz PS, Hadac EM, Miller LJ, LaRusso NF.

Regul Pept. 2001 Feb 2;97(1):1-6.

PMID:
11166400
18.

Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.

Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ.

J Biol Chem. 2001 Feb 9;276(6):4236-44. Epub 2000 Oct 24.

19.

Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.

Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ.

J Pharmacol Exp Ther. 2000 Nov;295(2):682-8.

PMID:
11046106
20.

Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues.

Asmann YW, Dong M, Ganguli S, Hadac EM, Miller LJ.

Mol Pharmacol. 2000 Nov;58(5):911-9.

PMID:
11040037
21.
24.
26.

Cellular distribution of secretin receptor expression in rat pancreas.

Ulrich CD 2nd, Wood P, Hadac EM, Kopras E, Whitcomb DC, Miller LJ.

Am J Physiol. 1998 Dec;275(6):G1437-44. doi: 10.1152/ajpgi.1998.275.6.G1437.

PMID:
9843782
27.

Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis.

Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, Miller LJ.

J Pharmacol Exp Ther. 1998 Aug;286(2):593-8.

PMID:
9694908
28.

Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking.

Go WY, Holicky EL, Hadac EM, Rao RV, Miller LJ.

Am J Physiol. 1998 Jul;275(1):G56-62. doi: 10.1152/ajpgi.1998.275.1.G56.

PMID:
9655684
29.

Direct identification of a second distinct site of contact between cholecystokinin and its receptor.

Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller LJ.

J Biol Chem. 1998 May 22;273(21):12988-93.

32.
33.
35.

Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor.

Holtmann MH, Hadac EM, Ulrich CD, Miller LJ.

J Pharmacol Exp Ther. 1996 Nov;279(2):555-60.

PMID:
8930157
36.

Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation.

Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, Miller LJ.

Pancreas. 1996 Aug;13(2):130-9.

PMID:
8829180
37.

Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor.

Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ.

J Biol Chem. 1996 Jun 21;271(25):14944-9.

38.

Insulation of a G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell.

Roettger BF, Rentsch RU, Hadac EM, Hellen EH, Burghardt TP, Miller LJ.

J Cell Biol. 1995 Aug;130(3):579-90.

40.

Preparation of radiolabeled photolabile probes of high specific radioactivity for affinity labeling.

Miller LJ, Hadac EM, Powers SP.

Anal Biochem. 1994 Aug 1;220(2):434-5. No abstract available.

PMID:
7978292
41.

Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors.

Ulrich CD 2nd, Pinon DI, Hadac EM, Holicky EL, Chang-Miller A, Gates LK, Miller LJ.

Gastroenterology. 1993 Nov;105(5):1534-43.

PMID:
8224659
42.

Binding of a phenethyl ester analogue of cholecystokinin to the solubilized pancreatic cholecystokinin receptor: use in ligand-affinity chromatography.

Miller LJ, Hadac EM, Gates LK, Gaisano HY.

Biochem Biophys Res Commun. 1992 Mar 16;183(2):396-404.

PMID:
1550549
43.

Purification and characterization of the rat pancreatic cholecystokinin receptor.

Duong LT, Hadac EM, Miller LJ, Vlasuk GP.

J Biol Chem. 1989 Oct 25;264(30):17990-6.

44.

Structural analysis of a distinct subtype of CCK receptor on human gastric smooth muscle tumors.

Pearson RK, Hadac EM, Miller LJ.

Am J Physiol. 1989 Jun;256(6 Pt 1):G1005-10.

PMID:
2735406
45.
46.
47.

Establishment of a new short, protease-resistant, affinity labeling reagent for the cholecystokinin receptor.

Pearson RK, Powers SP, Hadac EM, Gaisano H, Miller LJ.

Biochem Biophys Res Commun. 1987 Aug 31;147(1):346-53.

PMID:
2443134
48.
49.

Preparation and characterization of a new cholecystokinin receptor probe that can be oxidatively radioiodinated.

Pearson RK, Hadac EM, Miller LJ.

Gastroenterology. 1986 Jun;90(6):1985-91.

PMID:
3009263

Supplemental Content

Loading ...
Support Center